TD Cowen analyst Joseph Thome maintained a Hold rating on PTC Therapeutics (PTCT – Research Report) today and set a price target of $60.00. The ...

UBS lowered the firm’s price target on Kyverna Therapeutics (KYTX) to $12 from $13 and keeps a Buy rating on the shares. The company reported ...

DelveInsight's "LUXTURNA Market Size, Forecast, and Market Insight Report" highlights the details around LUXTURNA, a one-time ...

Roche has recently launched a “fundamental reorganization” of Spark Therapeutics, the gene therapy unit the Swiss pharma bought for $4.3 billion in 2019. Roche described the restructuring in ...

It's hard watching a former local darling get restructured, but federal funding blocks and a lack of local investors are more front-of-mind.

LUXTURNA has significant market potential due to the high unmet need for effective treatments in rare genetic conditions. With its FDA approval for specific mutations in the RPE65 gene, it offers ...

Roche is to buy gene therapy firm Spark Therapeutics for $4.8 billion, adding an already-approved treatment for inherited blindness to its portfolio, and boosting its pipeline with a series of ...

Spark had an unspecified number of layoffs last summer after discontinuing work on several early-stage products, Endpoints News reported. The company now employs “more than 600,” Bradley said ...

Kyverna Therapeutics logo (PRNewsfoto/Kyverna Therapeutics) "Kyverna's first year as a public company was a transformative one, as we demonstrated our leadership position in autoimmune CAR T.

Christmas has come a few days early for Spark Therapeutics after the FDA approved its ground-breaking gene therapy for a rare eye disease. It looked likely that the FDA would approve the US ...

Chevy is resurrecting both the Spark and EUV nameplates with the all-new, affordable Chevy Spark EUV. GM hopes its new, 249-mile range EV will be a “game changer” that helps accelerate the ...